Proteinuria among primarily sirolimus treated live-donor renal transplant recipients' long-term experience.

摘要: OBJECTIVES Recent evidence of a high incidence proteinuria among de novo sirolimus-based regimens has been reported renal transplant patients at short-term follow-up. We report on long-term evaluation maintained such regimen. MATERIALS AND METHODS Between May 2001 and January 2003, 132 received allograft from living donor were randomized to 2 groups (steroids/sirolimus/tacrolimus, n=65) (steroids/sirolimus/mycophenolate mofetil, n=67): Both basiliximab induction. Retrospective review those was performed, 5 years posttransplant with particular emphasis the proteinuria. RESULTS The 5-year 29.2% 38.8% sirolimus/tacrolimus sirolimus/mycophenolate mofetil group. Single DR-matched (P = .016) acute rejection .039) associated significantly higher Moreover, presence mesangial matrix increased .015), glomerulosclerosis .014), in 1-year protocol biopsies, found have positive predictive value for current future incidences Proteinuria be significant inferior graft outcome. Recurrent original kidney disease, glomerulopathy, glomerulopathy responsible early cases nephrotic range (first years), while presented later attributed chronic nephropathy. CONCLUSIONS become recognized, serious event primarily sirolimus-treated transplants patients, which is most probably glomerular origin. It shown that exerts bad prognostic effect upon function subsequent survival